Hansoh Pharma's Ameile (Ametinib Mesylate Tablets) is now available nationwide!

01 Ameile on the production line

In order to meet the medication needs of patients, Ameile has entered the stage of mass production.

02 Boxes of Ameile ready to go

Racing against time, Ameile loading proceeds in a tense and orderly manner.

03 Ameile to be shipped at full speed

Time is hope. Carrying the hope for a better tomorrow, Ameile starts its first journey!

About Ameile (Ametinib Mesylate Tablets)

Ameile (Ametinib Mesylate Tablets) is a Class 1 innovative drug independently developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. It is the world's second third-generation EGFR-TKI innovative drug and the world's first third-generation EGFR-TKI with a median progression-free survival (mPFS) of more than one year (second-line use), used for the treatment of "adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and are positive for T790M mutation".

The launch of Ameile provides clinicians with a new, highly efficacious, safe and accessible option, and brings the hope for long-term and high-quality survival to more patients with advanced NSCLC.